Patent ID: 8404451

Claim:
A method for assessing the onset, progression, or regression of a diabetic condition characterized by abnormal levels of glycated CD59 comprising: digesting CD59 in a sample obtained for a subject; identifying a peptide yielded by the digestion of CD59 in the sample using mass spectrometry, wherein the peptide identified is a peptide of the amino acid sequence set forth as AGLQVYNK (SEQ ID NO:8), CWK, FEHCNFNDVTTR (SEQ ID NO:9), or CWKFEHCNFNDVTTR (SEQ ID NO:10), wherein the residue K of SEQ ID NO:10 is glycated or non-glycated; quantitating the identified peptides as a determination of the level of glycated CD59 in the sample; and comparing the level to a control as an assessment of the onset, progression, or regression of the condition.